PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

~Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Phase 2

A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of t…

Uterine SarcomaUterine LeiomyosarcomaEndometrial Stromal Sarcoma+6 more

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07467772